Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
biote Corp (BTMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: BTMD (1-star) is a SELL. SELL since 5 days. Profits (-30.43%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.88
1 Year Target Price $4.88
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.28% | Avg. Invested days 24 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 142.60M USD | Price to earnings Ratio 3.39 | 1Y Target Price 4.88 |
Price to earnings Ratio 3.39 | 1Y Target Price 4.88 | ||
Volume (30-day avg) 6 | Beta 1.21 | 52 Weeks Range 2.76 - 6.98 | Updated Date 08/15/2025 |
52 Weeks Range 2.76 - 6.98 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.88 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate 0.08 | Actual 0.1 |
Profitability
Profit Margin 15.73% | Operating Margin (TTM) 22% |
Management Effectiveness
Return on Assets (TTM) 25.25% | Return on Equity (TTM) - |
Valuation
Trailing PE 3.39 | Forward PE 6.34 | Enterprise Value 182737326 | Price to Sales(TTM) 0.72 |
Enterprise Value 182737326 | Price to Sales(TTM) 0.72 | ||
Enterprise Value to Revenue 0.92 | Enterprise Value to EBITDA 3.36 | Shares Outstanding 31692700 | Shares Floating 15587751 |
Shares Outstanding 31692700 | Shares Floating 15587751 | ||
Percent Insiders 12.94 | Percent Institutions 63.82 |
Upturn AI SWOT
biote Corp
Company Overview
History and Background
Biote Corp focuses on precision and preventative hormone optimization, founded to provide a comprehensive approach to hormone health.
Core Business Areas
- Hormone Optimization: Biote's primary focus is on bioidentical hormone replacement therapy (BHRT) via subcutaneous pellets.
- Nutraceuticals: The company offers a line of nutraceutical products designed to complement hormone therapy.
- Training and Certification: Biote provides training and certification programs for healthcare practitioners to administer Biote's BHRT methods.
Leadership and Structure
Key leadership includes a CEO, CFO, and Chief Medical Officer. The organizational structure includes departments for research and development, sales, marketing, operations, and regulatory compliance.
Top Products and Market Share
Key Offerings
- Biote Method (BHRT Pellets): Biote's patented hormone pellet therapy aims to optimize hormone levels. Market share data is proprietary, but Biote is a leading provider in the pellet BHRT market. Revenue data is not public. Competitors: SottoPelle, EvexiPEL.
- Biote Nutraceuticals: Biote offers a range of nutraceuticals designed to support hormone health and overall wellness. Market share data is fragmented as it is a large Nutraceutical market. Competitors: Thorne Research, Metagenics, Designs for Health.
Market Dynamics
Industry Overview
The BHRT market is growing, driven by increasing awareness of hormone-related health issues and demand for personalized medicine. The nutraceutical market is also experiencing growth due to growing consumer interest in health and wellness.
Positioning
Biote is positioned as a leading provider of hormone optimization therapies and integrated wellness solutions, emphasizing training and certification to ensure quality standards.
Total Addressable Market (TAM)
The estimated TAM for BHRT and related wellness products is $50 billion. Biote is capturing a growing segment through its practitioner network and integrated offerings.
Upturn SWOT Analysis
Strengths
- Strong brand recognition in the BHRT market
- Proprietary hormone pellet formulation and delivery system
- Extensive network of certified healthcare providers
- Integrated approach combining BHRT and nutraceuticals
Weaknesses
- Limited scientific data supporting long-term efficacy
- Reliance on a network of practitioners creates dependancy and added costs
- High cost of BHRT treatment
- Competition from alternative hormone therapies
Opportunities
- Expanding the network of certified healthcare providers
- Developing new BHRT formulations and delivery methods
- Expanding into international markets
- Conducting clinical trials to validate the efficacy of BHRT
Threats
- Regulatory changes impacting BHRT practices
- Competition from larger pharmaceutical companies
- Negative publicity regarding BHRT safety
- Economic downturn impacting consumer spending
Competitors and Market Share
Key Competitors
- NVGN
- PRGO
- VRX
Competitive Landscape
Biote competes with other BHRT providers and pharmaceutical companies offering hormone therapies. Its competitive advantage lies in its proprietary pellet formulation and extensive training network.
Major Acquisitions
None
- Year: 2024
- Acquisition Price (USD millions): 0
- Strategic Rationale: NA
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is unavailable without live access.
Future Projections: Growth is projected in the BHRT market driven by practitioners adopting the technique.
Recent Initiatives: Recent initiatives focus on expanding the network of certified providers and launching new nutraceutical products.
Summary
Biote Corp holds a strong position in the growing BHRT market. They stand out with a growing network of certified providers. The company should focus on data driven strategies for increased efficiency. It needs to focus on proving efficacy through more rigorous clinical trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
Disclaimers:
Data is based on publicly available information and may not be entirely accurate. The analysis is for informational purposes only and does not constitute financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About biote Corp
Exchange NASDAQ | Headquaters Irving, TX, United States | ||
IPO Launch date 2021-04-28 | CEO & Director Mr. Bret Christensen | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 217 | Website https://www.biote.com |
Full time employees 217 | Website https://www.biote.com | ||
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.